– USA, WA – Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the appointment of Dr. Andreas Busch (Ph.D.) to its Board of Directors.
About Dr. Andreas Busch
Dr. Andreas Busch is the former EVP and CSO at Shire Plc and Head of Drug Discovery at Bayer and is currently CSO at Cyclerion Therapeutics, Inc. He brings over twenty years of pharmaceutical industry executive experience in drug discovery R&D leadership positions.
Previously, Dr. Busch served as EVP, Head of Research & Development, and CSO at Shire Plc. Prior to joining Shire, he held several senior leadership positions in his 13-year tenure at Bayer group, most recently as EVP and Head of Global Drug Discovery. Earlier in his career, Dr. Busch was the Global Head of Cardiovascular Research at Hoechst and Sanofi-Aventis. Dr. Busch has served as a member of numerous Supervisory and Scientific Boards of research institutions and companies, including the German Cancer Research Center, the University of Tübingen, the Max Delbrück Center, and the Max Planck Institute of Molecular Genetics, as well as Takeda and start-up companies, such as Omeicos and BerlinCures. He also holds the title of Extraordinary Professor of Pharmacology at the Johann Wolfgang Goethe University in Frankfurt, Germany.
“Absci has a unique and powerful combination of cutting-edge AI and synthetic biology technologies that synergize to enable identification of promising drug candidates with extraordinary efficiency. I look forward to helping Absci apply its platform to achieve our shared goal of bringing better drugs to patients faster,” said Dr. Busch.
Dr. Busch received his license to practice Pharmacy and Ph.D. in Pharmacology from the Johann-Wolfgang-Goethe-University, Frankfurt. He is the author of over 400 publications and abstracts, and he received the prestigious Sir Bernard Katz and Franz Volhard Awards for his work on renal and cardiac ion channels and transporters.
About Absci
Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs.
For more information: https://www.absci.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
